Bio-Rad Laboratories, Inc. (BIO) Upgraded by TheStreet to “B-“
Bio-Rad Laboratories, Inc. (NYSE:BIO) was upgraded by stock analysts at TheStreet from a “c+” rating to a “b-” rating in a note issued to investors on Monday.
BIO has been the subject of several other reports. Zacks Investment Research upgraded shares of Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a research report on Tuesday, November 7th. Deutsche Bank AG restated a “buy” rating and set a $255.00 price objective on shares of Bio-Rad Laboratories in a research report on Monday, September 18th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $260.00.
Shares of Bio-Rad Laboratories (BIO) opened at $253.22 on Monday. Bio-Rad Laboratories has a one year low of $169.19 and a one year high of $268.40. The stock has a market cap of $7,540.54, a PE ratio of 80.77, a P/E/G ratio of 3.84 and a beta of 0.88. The company has a quick ratio of 2.77, a current ratio of 4.06 and a debt-to-equity ratio of 0.15.
Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, November 2nd. The medical research company reported $0.91 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.54 by $0.37. Bio-Rad Laboratories had a net margin of 1.15% and a return on equity of 3.44%. The business had revenue of $535.00 million during the quarter, compared to the consensus estimate of $507.99 million. During the same period last year, the business posted $0.62 EPS. Bio-Rad Laboratories’s revenue was up 5.2% on a year-over-year basis. equities analysts predict that Bio-Rad Laboratories will post 2.65 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Bio-Rad Laboratories, Inc. (BIO) Upgraded by TheStreet to “B-“” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/11/15/bio-rad-laboratories-inc-bio-upgraded-by-thestreet-to-b.html.
Institutional investors and hedge funds have recently made changes to their positions in the company. Canada Pension Plan Investment Board bought a new position in shares of Bio-Rad Laboratories during the second quarter worth approximately $113,000. Pacad Investment Ltd. bought a new position in shares of Bio-Rad Laboratories during the second quarter worth approximately $113,000. First Manhattan Co. increased its holdings in shares of Bio-Rad Laboratories by 71.6% during the third quarter. First Manhattan Co. now owns 599 shares of the medical research company’s stock worth $133,000 after purchasing an additional 250 shares during the period. Turner Investments LLC bought a new position in shares of Bio-Rad Laboratories during the second quarter worth approximately $136,000. Finally, Meeder Asset Management Inc. increased its holdings in shares of Bio-Rad Laboratories by 3,333.3% during the third quarter. Meeder Asset Management Inc. now owns 618 shares of the medical research company’s stock worth $137,000 after purchasing an additional 600 shares during the period. 64.27% of the stock is currently owned by institutional investors.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.